Teva
Teva collaborates on skin disease treatment, releases targets
Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a phase 1b trial for the treatment of vitiligo
Teva seeks startups to help solve global pharmaceutical challenges
Placing the focus on the therapist
Does a common heart attack pill help everyone? Studies disagree
Teva agreed to pay Oklahoma $85m to settle opioid claims
Claims against Teva focused on the branded opioid products Actiq and Fentora as well as generic painkillers it produced.
Teva shares tumble as company faces price-fixing lawsuit
The Israeli pharmaceutical company is being sued in the US following an alleged price-fixing conspiracy worth "many billions of dollars."
Teva at the center of a lawsuit for raising drug prices
According to the Bloomberg news agency, more than a dozen present and former executives of leading generic companies have been sued.
Teva's new migraine drug helps contain profit fall
Teva has reduced its spending by $2.5 billion since initiating the restructuring last year.
Grotsky debuts as Teva Naot spokesmodel
The media and television personality Dana Grotsky, who – with Guy Pines – cohosts Good Evening With Guy Pines.
Teva hopes generic EpiPen will sell well in U.S. market
An EpiPen, or epinephrine auto-injector, is a medication used to treat serious allergic reactions in emergencies.
U.S. settles with Teva over keeping generic drugs off market
The agency has said that the deals cost consumers billions annually in higher drug costs.
Teva CEO: Tough year ahead, but we're hitting cost-cutting targets
The successful Israeli-based generic medication manufacturer has been forced to downsize, but emphasized there will be no second round of restructuring or new site closures.
Israeli scientists abroad: We want to come home
At a workshop in Tel Aviv, the country’s brightest face a hard choice. Can they bring home the skills they have acquired?
Israeli drug giant Teva to move offices to Tel Aviv
"The expected move-in date will be mid-2020," Teva SVP global human resources Mark Sabag told Globes.
